Seattle Genetics, Inc. Presents Data From Novel Antibody-Drug Conjugate (ADC) SGN-CD19A At American Society of Hematology 2013

Seattle Genetics, Inc. (Nasdaq: SGEN) today presented interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including acute lymphoblastic leukemia (ALL), at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013. SGN-CD19A is an ADC targeting CD19, a protein expressed uniformly on almost all B-cell malignancies.

Help employers find you! Check out all the jobs and post your resume.